AEON Biopharma Files 8-K on Corporate Actions
Ticker: AEON · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1837607
Sentiment: neutral
Topics: corporate-governance, filing, amendment
Related Tickers: AEON
TL;DR
AEON Biopharma filed an 8-K detailing corporate changes and votes. Stay tuned for updates.
AI Summary
AEON Biopharma, Inc. filed an 8-K on February 24, 2025, reporting on several items including material modifications to security holder rights, amendments to its articles of incorporation, and submission of matters to a vote. The filing also includes Regulation FD disclosures and financial statements/exhibits. AEON Biopharma, formerly Priveterra Acquisition Corp., is incorporated in Delaware and based in Irvine, CA.
Why It Matters
This 8-K filing indicates significant corporate governance and structural updates for AEON Biopharma, Inc., which could impact security holders and the company's operational framework.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative news or significant financial distress.
Key Numbers
- 001-40021 — SEC File Number (Identifies the company's filing history with the SEC.)
- 85-3940478 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- February 24, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Irvine, CA (location) — Business address city and state
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item information, but the specific details of these modifications are not provided in the excerpt.
What were the key amendments to AEON Biopharma's articles of incorporation or bylaws?
The filing lists 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item, but the specific amendments are not detailed in the provided text.
What matters were submitted to a vote of security holders?
The filing notes 'Submission of Matters to a Vote of Security Holders' as an item, but the nature of these matters is not specified in the excerpt.
What is the significance of the Regulation FD Disclosure mentioned?
Regulation FD Disclosure indicates that the company is making public disclosures to ensure broad public dissemination of material non-public information, as required by SEC rules.
When did AEON Biopharma change its name from Priveterra Acquisition Corp.?
The filing states the former company name was Priveterra Acquisition Corp. and the date of name change was 20201222.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding AEON Biopharma, Inc. (AEON).